Adagene Inc - חוב לטווח קצר של החברה ADAG

Adagene business growth depends on antibody test outcomes and partner payments amid stable cash reserves. Research centers in the US and China rely on external manufacturing plants for drug production. This short-term debt chart demonstrates the impact of the NEObody platform on financial stability, with the indicator reaching 0.01, confirming the precision of AI-driven drug design.

This indicator measures the total volume of liabilities with a maturity of up to one year, reflecting management's ability to manage liquidity and minimize default risks. The stability of current loans and borrowings confirms that Adagene effectively funds R&D through partner payments and licensing fees, maintaining financial equilibrium without a critical dependence on short-term debt capital.